Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07221344 | Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease | PHASE1 | RECRUITING | 112 | — | — | Nov 18, 2025 | Jun 1, 2027 | May 28, 2026 | 3 | Canada, New Zealand |
| Arm | Type | Description |
|---|---|---|
| ARO-MAPT-SC | EXPERIMENTAL | ARO-MAPT-SC injection |
| Placebo | PLACEBO_COMPARATOR | Sterile normal saline (0.9%) |
| Name | Type | Description |
|---|---|---|
| ARO-MAPT-SC | DRUG | • single or multiple doses of ARO-MAPT-SC by subcutaneous (SC) injection |
| Placebo | DRUG | • calculated volume to match active treatment by SC administration |
Inclusion Criteria (All Participants): * Body mass index between 18.0 and 35.0 kg/m\^2 at Screening * Not pregnant or breast-feeding * Able and willing to provide written informed consent prior to the performance of any study specific procedures * Participants of childbearing potential must agree t...